4.6 Article

Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score

期刊

MOVEMENT DISORDERS
卷 35, 期 5, 页码 774-780

出版社

WILEY
DOI: 10.1002/mds.27974

关键词

G2019S; genetics; LRRK2; Parkinson's disease; polygenic risk score

资金

  1. Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services [ZO1 AG000949]
  2. Michael J. Fox Foundation
  3. AbbVie
  4. Allergan
  5. Avid Radiopharmaceuticals
  6. Biogen
  7. BioLegend
  8. Bristol-Myers Squibb
  9. Celgene
  10. Denali Incorporated
  11. GE Healthcare
  12. Genentech
  13. GlaxoSmithKline
  14. Eli Lilly and Company
  15. Lundbeck
  16. Merck Co.
  17. Meso Scale Discovery
  18. Pfizer
  19. Piramal
  20. Prevail Therapeutics
  21. Roche
  22. Sanofi Genzyme
  23. Servier Laboratories
  24. Takeda
  25. Teva
  26. UCB
  27. Verily
  28. Voyager Therapeutics
  29. Golub Capital
  30. Michael J. Fox Foundation for Parkinson's research
  31. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003169, ZIANS003154] Funding Source: NIH RePORTER
  32. NATIONAL INSTITUTE ON AGING [ZIAAG000958, ZIAAG000951, ZIAAG000957, ZIAAG000949] Funding Source: NIH RePORTER
  33. MRC [MR/T04604X/1, UKDRI-3003, MR/L023784/2] Funding Source: UKRI

向作者/读者索取更多资源

Background Although the leucine-rich repeat kinase 2 p.G2019S mutation has been demonstrated to be a strong risk factor for PD, factors that contribute to penetrance among carriers, other than aging, have not been well identified. Objectives To evaluate whether a cumulative genetic risk identified in the recent genome-wide study is associated with penetrance of PD among p.G2019S mutation carriers. Methods We included p.G2019S heterozygote carriers with European ancestry in three genetic cohorts in which the mutation carriers with and without PD were selectively recruited. We also included the carriers from two data sets: one from a case-control setting without selection of mutation carriers and the other from a population sampling. Associations between polygenic risk score constructed from 89 variants reported recently and PD were tested and meta-analyzed. We also explored the interaction of age and PRS. Results After excluding eight homozygotes, 833 p.G2019S heterozygote carriers (439 PD and 394 unaffected) were analyzed. Polygenic risk score was associated with a higher penetrance of PD (odds ratio: 1.34; 95% confidence interval: [1.09, 1.64] per +1 standard deviation; P = 0.005). In addition, associations with polygenic risk score and penetrance were stronger in the younger participants (main effect: odds ratio 1.28 [1.04, 1.58] per +1 standard deviation; P = 0.022; interaction effect: odds ratio 0.78 [0.64, 0.94] per +1 standard deviation and + 10 years of age; P = 0.008). Conclusions Our results suggest that there is a genetic contribution for penetrance of PD among p.G2019S carriers. These results have important etiological consequences and potential impact on the selection of subjects for clinical trials. (c) 2020 International Parkinson and Movement Disorder Society

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据